Publication | Closed Access

Assessment of the biological and pharmacological effects of the ανβ3 and ανβ5 integrin receptor antagonist, cilengitide (EMD 121974), in patients with advanced solid tumors

Molecular PharmacologyOncologyChemoprevention StrategyMedicineReceptor AntagonistAdvanced Solid TumorsPharmacotherapyAnti-cancer AgentCancer TreatmentPharmacologyRadiation OncologyCancer ResearchTumor BiologyEmd 121974